Low-density lipoprotein enhances platelet secretion via integrin-alphaIIbbeta3-mediated signaling.
LDL is known to increase the sensitivity of human platelets for agonists and to induce aggregation and secretion independently at high concentrations, but its mechanism of action is largely obscure. To clarify how LDL increases platelet sensitivity, cells were incubated in lipoprotein-poor plasma and treated with collagen at a concentration that induced approximately 20% secretion of 14C-serotonin. Preincubation with LDL (30 minutes at 37 degreesC) enhanced secretion in a dose-dependent manner to 60+/-14% at a concentration of 2 g LDL protein/L. Similar stimulation by LDL was seen when secretion was induced by the thrombin receptor-activating peptide. This enhancement was strongly reduced (1) in the presence of monoclonal antibody PAC1 against activated alphaIIbbeta3, a polyclonal antibody against alphaIIb, and in the presence of the fibrinogen peptides GRGDS and HHLGGAKQAGDV; (2) in alphaIIbbeta3-deficient platelets; and (3) after dissociation of alphaIIbbeta3. In contrast, binding of 125I-LDL to normal platelets in the presence of PAC1, anti-alphaIIb, GRGDS, and HHLGGAKQAGDV, and to alphaIIbbeta3-deficient platelets was normal. LDL increased the surface expression of fibrinogen in lipoprotein-poor plasma and fibrinogen-free medium, suggesting that extracellular and granular fibrinogen bind to alphaIIbbeta3 after platelet-LDL interaction. Platelets deficient in fibrinogen (<0.5% of normal) or von Willebrand Factor (<1% of normal) but containing normal amounts of other ligands for alphaIIbbeta3 preserved responsiveness to LDL, indicating that occupancy of alphaIIbbeta3 was not restricted to fibrinogen. Inhibition of protein kinase C (bisindolylmaleimide) diminished fibrinogen binding and sensitization by LDL; inhibition of tyrosine kinases (herbimycin A) left fibrinogen binding unchanged but diminished sensitization by LDL. We conclude that an increased concentration of LDL, such as observed in homozygous familial hypercholesterolemia, sensitizes platelets to stimulation by collagen and thrombin receptor-activating peptide via ligand-induced outside-in signaling through integrin-alphaIIbbeta3.
Hackeng
C M
CM
Department of Clinical Chemistry, University Hospital Utrecht, and Institute for Biomembranes, Utrecht University, The Netherlands.
Huigsloot
M
M
Pladet
M W
MW
Nieuwenhuis
H K
HK
van Rijn
H J
HJ
Akkerman
J W
JW
D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D003094:Collagen / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005340:Fibrinogen / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D008077:Lipoproteins, LDL / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000502:physiology*; D011493:Protein Kinase C / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000502:physiology; D012701:Serotonin / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*